By Fineline Cube 
Shanghai BDgene Technology Co., Ltd. announced the successful closing of a financing round securing hundreds of millions of renminbi, led by EFung Capital with participation from Hangzhou Xiacheng District State-owned Investment Holding and UMC Capital.
Investment Highlights
| Item | Detail |
|---|---|
| Lead Investor | EFung Capital |
| Co-Investors | Hangzhou Xiacheng District State-owned Investment Holding, UMC Capital |
| Amount Raised | Hundreds of millions RMB |
| Company Focus | Gene therapy platforms and product development |
| Key Platforms | BD-VLP (virus-like particle), BD-Lenti (lentiviral vector) |
Proprietary Technology Platforms
- BD-VLP Platform: Clinically validated virus-like particle technology featuring:
- Transient expression
- High cargo capacity
- High targeting efficiency
- High editing efficiency
- Regulatory Recognition: BD-VLP platform included in the National Health Commission’s “New Gene Therapy Technologies” initiative under the encouraged category
- BD-Lenti Platform: Next-generation lentiviral vector system designed for stable gene delivery across multiple therapeutic applications
Product Pipeline & Clinical Progress
| Therapeutic Area | Pipeline Status | Key Candidates |
|---|---|---|
| Viral Infections | Phase II | BD111 (world’s first CRISPR-based antiviral gene-editing drug) |
| Rare Diseases | Preclinical/IND-enabling | Multiple candidates |
| Glaucoma | Preclinical/IND-enabling | Multiple candidates |
| Tumor Vaccines | Preclinical/IND-enabling | Multiple candidates |
| CNS Disorders | Preclinical/IND-enabling | Multiple candidates |
The company has established over 10 product pipelines leveraging its dual-platform approach, with BD111 representing the most advanced candidate as the world’s first CRISPR-based antiviral gene-editing therapy now in Phase II trials.
Strategic Outlook
- Platform Validation: The significant investment validates BDgene’s dual-platform strategy and technological differentiation in the competitive gene therapy landscape
- Regulatory Pathway: With NHC recognition of BD-VLP technology, the company benefits from favorable regulatory positioning in China
- Development Acceleration: New capital will accelerate clinical development programs and expand manufacturing capabilities for both delivery platforms
- Market Positioning: BDgene is positioned at the forefront of China’s emerging gene therapy sector with proprietary technologies addressing multiple high-value therapeutic areas
Forward‑Looking Statements
This brief contains forward-looking statements regarding BDgene’s financing, clinical development timelines, and commercial expectations. Actual results may differ due to risks including regulatory approvals, clinical trial outcomes, and competitive dynamics.-Fineline Info & Tech